Government Affairs and Public Policy Partner Felicia Leborgne Nowels provided Bloomberg Law with her thoughts on the Food and Drug Administration's (FDA) recently announced plan to streamline its guidance practices. Nowels noted that this initiative arrives at a pivotal moment as President-elect Donald Trump prepares to implement his transparency agenda within the government, which may significantly influence the FDA's operations moving forward.

Nowels emphasized that the incoming administration's approach will impact the FDA's guidance strategies.

“We have a very educated guess that this administration will be focused on transparency, and I do think that the guidance plan supports that transparency,” Nowels told the publication.

“A counterpoint to it is, if Trump and the FDA administration take the historic approach of less regulatory oversight, it’ll be interesting to see if the administration releases new guidance,” she added.